Players in Celiac Disease Drugs Market Focus on Adopting Partnership Strategies to Expand Their Product Portfolio

Coeliac disorder is a health condition in which your body attacks your digestive tissues when you consume gluten. This damages your small intestine (small intestine) due to the damage it can cause to your cells, so that you're not able to absorb nutrients properly. The most common food allergies in infants and toddlers are milk, peanuts, soy, wheat and eggs. The main reason young children suffer from a food allergy is that their immune systems haven't completely developed yet, and they are still sensitive to allergens. The other main reason young people suffer from this condition is that they've been exposed to too much artificial sweeteners and may even have an intolerance to wheat itself.

The celiac disease drugs market is witnessing significant investment. In April 2021, Sanford Health, a healthcare provider, launched the Pledge Study to identify and predict which children may be at risk of developing type 1 diabetes and celiac disease with the help of US$ 1.3 million grant from Leona M. and Harry B. Helmsley Charitable Trust. Similarly, in December 2020, The Canadian Celiac Association opened its request for two grant proposals in aid of research in the field of celiac disease and gluten sensitivity.

R&D in gliadin nanoparticles is expected to offer lucrative growth opportunities for players in the celiac disease drugs market. In February 2020, a study by University of Helsinki reported that injection of negatively charged 500-nm poly(lactide-co-glycolide) nanoparticles encapsulating gliadin protein nanoparticles can aid in the treatment of celiac disease. The nanoparticles induced immune tolerance in animal models of autoimmune disease.

Coherent Market Insights celebrating 5th anniversary and offering 1000 USD off for all reports. Let’s celebrate with us.
Click for promo code: https://www.coherentmarketinsights.com/promo/buynow/168

Players in the celiac disease drugs market are focused on adopting partnership strategies to expand their product portfolio. In February 2021, Beyond Celiac, a catalyst for a celiac disease cure in the U.S., announced a two-year joint research grant program with Janssen Research & Development, LLC (Janssen) through its World Without Disease Accelerator group. The program focuses on R&D in risk detection, prevention, interception, and cure of celiac disease. Similarly, in September 2020, Beyond Celiac partnered with Provention Bio, Inc. to provide clinical trial recruitment for the biopharmaceutical company’s Phase 2b study assessing the efficacy of PRV-015 (an anti-interleukin-15 monoclonal antibody) for the treatment of celiac disease.

Players in the celiac disease drugs market are also focused on adopting M&A strategies to expand their product portfolio. For instance, in February 2020, Takeda Pharmaceutical Company Limited acquired PvP Biologics, Inc. following the conclusion of phase 1 proof-of-mechanism study of investigational medicine TAK-062 (Kuma062), a potential best-in-class, highly potent super glutenase – a protein that degrades ingested gluten, for the treatment of uncontrolled celiac disease.

Read more @ https://www.coherentmarketinsights.com/ongoing-insight/celiac-disease-drugs-market-168

Contact Us:
Mr. Shah
Senior Client Partner – Business Development
Coherent Market Insights
Phone:
US: +1-206-701-6702
UK: +44-020-8133-4027
Japan: +81-050-5539-1737
India: +91-848-285-0837
Email: sales@coherentmarketinsights.com
Website: https://www.coherentmarketinsights.com

About Us:
Coherent Market Insights (CMI) is a global market intelligence and consulting organization focused on assisting plethora of clients achieve transformational growth by helping them make critical business decisions. The company is headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. The company’s client base includes players from across various business verticals in over 47 countries globally. It takes pride in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies, to not-for-profit organization, and start-ups looking to establish a foothold in the market.

This release was published on openPR.